{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:09:42Z","timestamp":1779232182103,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11523-025-01182-0","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:10:45Z","timestamp":1762186245000},"page":"979-989","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study"],"prefix":"10.1007","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct04538664","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rachel E.","family":"Sanborn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Del Rosario Garcia Campelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Delmonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Alatorre-Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Dooms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua K.","family":"Sabari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archan","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasuh","family":"Buyukkaramikli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nolen","family":"Perualila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Proskorovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Dearden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honeylet","family":"Wortman-Vayn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parthiv J.","family":"Mahadevia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland E.","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trishala","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahadi","family":"Baig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"Suppl. 1","key":"1182_CR1","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/onc.2009.198","volume":"28","author":"AF Gazdar","year":"2009","unstructured":"Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl. 1):S24-31. https:\/\/doi.org\/10.1038\/onc.2009.198.","journal-title":"Oncogene"},{"key":"1182_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","volume":"4","author":"S Vyse","year":"2019","unstructured":"Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4:5. https:\/\/doi.org\/10.1038\/s41392-019-0038-9.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1182_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","volume":"12","author":"ME Arcila","year":"2013","unstructured":"Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2):220\u20139. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0620.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1182_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","volume":"8","author":"GR Oxnard","year":"2013","unstructured":"Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179\u201384. https:\/\/doi.org\/10.1097\/JTO.0b013e3182779d18.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1182_CR5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","volume":"13","author":"JW Riess","year":"2018","unstructured":"Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.019.","journal-title":"J Thorac Oncol"},{"issue":"13","key":"1182_CR6","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","volume":"76","author":"SL Moores","year":"2016","unstructured":"Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76(13):3942\u201353. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2833.","journal-title":"Cancer Res"},{"issue":"10","key":"1182_CR7","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1158\/1535-7163.Mct-20-0071","volume":"19","author":"S Vijayaraghavan","year":"2020","unstructured":"Vijayaraghavan S, Lipfert L, Chevalier K, Bushey BS, Henley B, Lenhart R, et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis. Mol Cancer Ther. 2020;19(10):2044\u201356. https:\/\/doi.org\/10.1158\/1535-7163.Mct-20-0071.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"1182_CR8","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","volume":"10","author":"J Yun","year":"2020","unstructured":"Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov. 2020;10(8):1194\u2013209. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0116.","journal-title":"Cancer Discov"},{"issue":"16","key":"1182_CR9","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee J-S, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391(16):1486\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2403614.","journal-title":"N Engl J Med"},{"issue":"1","key":"1182_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.117.","journal-title":"Ann Oncol"},{"issue":"22","key":"1182_CR11","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389(22):2039\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2306441.","journal-title":"N Engl J Med"},{"issue":"30","key":"1182_CR12","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/JCO.24.01001","volume":"42","author":"NB Leighl","year":"2024","unstructured":"Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study. J Clin Oncol. 2024;42(30):3593\u2013605. https:\/\/doi.org\/10.1200\/JCO.24.01001.","journal-title":"J Clin Oncol"},{"issue":"30","key":"1182_CR13","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391\u2013402. https:\/\/doi.org\/10.1200\/JCO.21.00662.","journal-title":"J Clin Oncol"},{"key":"1182_CR14","unstructured":"Rybrevant. Rybrevant\u00ae (amivantamab-vmjw) injection, for intravenous use [package insert]. Horsham (PA): Janssen Biotech, Inc.; Revised 2025. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/RYBREVANT-pi.pdf. Accessed 8 Aug 2025."},{"issue":"4","key":"1182_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.009.","journal-title":"Ann Oncol"},{"issue":"4","key":"1182_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(4):249\u201374. https:\/\/doi.org\/10.6004\/jnccn.2204.0023.","journal-title":"J Natl Compr Canc Netw"},{"key":"1182_CR17","unstructured":"Hendriks LE, Cortiula F, Mariamidze E, Martins Branco D, Pentheroudakis G, Reck M. Oncogene-Addicted Non-Small Cell Lung Cancer Living Guideline. 2025. https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-oncogene-addicted-metastatic-non-small-cell-lung-cancer. Accessed 27 Oct 2025."},{"key":"1182_CR18","unstructured":"Taiwan Food and Drug Administration. Assessment report. Rybrevant concentrate for solution for infusion 50 mg\/ml. 2021. https:\/\/www.fda.gov.tw\/tc\/includes\/GetFile.ashx?mid=189&id=38901&t=s. Accessed 27 Oct 2025."},{"key":"1182_CR19","unstructured":"Minist\u00e9rio da Sa\u00fade. Rybrevant (amivantamabe): nova indica\u00e7\u00e3o. https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/novos-medicamentos-e-indicacoes\/rybrevant-amivantamabe-nova-indicacao-1. Accessed 7 June 2024."},{"key":"1182_CR20","unstructured":"US Food and Drug Administration. FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications. Accessed 7 Mar 2024."},{"key":"1182_CR21","unstructured":"Rybrevant. Rybrevant (amivantamab) 350mg concentrate for solution for infusion [package insert]. Leiden: Janssen Biologics B.V. https:\/\/www.medicines.org.uk\/emc\/product\/13084\/smpc\/print. Accessed 8 Aug 2025."},{"key":"1182_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.lungcan.2021.10.020","volume":"162","author":"L Bazhenova","year":"2021","unstructured":"Bazhenova L, Minchom A, Viteri S, Bauml JM, Ou SI, Gadgeel SM, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021;162:154\u201361. https:\/\/doi.org\/10.1016\/j.lungcan.2021.10.020.","journal-title":"Lung Cancer"},{"key":"1182_CR23","unstructured":"Latimer NR, Abrams KR. NICE DSU Technical Support Document 16: adjusting survival time estimates in the presence of treatment switching. NICE Decision Support Unit Technical Support Documents. London: University of Sheffield; 2014. https:\/\/sheffield.ac.uk\/sites\/default\/files\/2022-06\/TSD16_Treatment_Switching.pdf. Assessed 27 Oct 2025"},{"key":"1182_CR24","unstructured":"Bell Gorrod H, Latimer NR, Abrams KR. NICE DSU Technical Support Document 24: adjusting survival time estimates in the presence of treatment switching: an update to TSD 16. 2024. https:\/\/sheffield.ac.uk\/sites\/default\/files\/2024-06\/TSD%2024%20-%20Adjusting%20Survival%20time%20Update%20to%20TSD%2016%20-%20FINAL.pdf. Assessed 27 Oct 2025."},{"issue":"3","key":"1182_CR25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jval.2019.10.015","volume":"23","author":"TR Sullivan","year":"2020","unstructured":"Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB, Karnon J. Adjusting for treatment switching in oncology trials: a systematic review and recommendations for reporting. Value Health. 2020;23(3):388\u201396. https:\/\/doi.org\/10.1016\/j.jval.2019.10.015.","journal-title":"Value Health"},{"issue":"2","key":"1182_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1467-9469.2007.00581.x","volume":"35","author":"G Li","year":"2008","unstructured":"Li G, Tseng CH. Non-parametric estimation of a survival function with two-stage design studies. Scand Stat Theory Appl. 2008;35(2):228\u201347. https:\/\/doi.org\/10.1111\/j.1467-9469.2007.00581.x.","journal-title":"Scand Stat Theory Appl"},{"key":"1182_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108548","volume":"203","author":"C Chouaid","year":"2025","unstructured":"Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, et al. Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study. Lung Cancer. 2025;203:108548. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108548.","journal-title":"Lung Cancer"},{"issue":"10","key":"1182_CR28","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0810699.","journal-title":"N Engl J Med"},{"issue":"7","key":"1182_CR29","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/j.cllc.2024.06.005","volume":"25","author":"M Reck","year":"2024","unstructured":"Reck M, De T, Paz-Ares L, Edmondson-Jones M, Yuan Y, Yates G, et al. Treatment-switching adjustment of overall survival in CheckMate 227 Part 1 evaluating first-line nivolumab plus ipilimumab versus chemotherapy for metastatic nonsmall cell lung cancer. Clin Lung Cancer. 2024;25(7):e362\u20138. https:\/\/doi.org\/10.1016\/j.cllc.2024.06.005.","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"1182_CR30","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2007.13.5335","volume":"26","author":"CK Daugherty","year":"2008","unstructured":"Daugherty CK, Ratain MJ, Emanuel EJ, Farrell AT, Schilsky RL. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008;26(8):1371\u20138. https:\/\/doi.org\/10.1200\/JCO.2007.13.5335.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1182_CR31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jval.2014.06.006","volume":"17","author":"L Jonsson","year":"2014","unstructured":"Jonsson L, Sandin R, Ekman M, Ramsberg J, Charbonneau C, Huang X, et al. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Value Health. 2014;17(6):707\u201313. https:\/\/doi.org\/10.1016\/j.jval.2014.06.006.","journal-title":"Value Health"},{"issue":"3","key":"1182_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1017\/S026646231600009X","volume":"32","author":"C Henshall","year":"2016","unstructured":"Henshall C, Latimer NR, Sansom L, Ward RL. Treatment switching in cancer trials: issues and proposals. Int J Technol Assess Health Care. 2016;32(3):167\u201374. https:\/\/doi.org\/10.1017\/S026646231600009X.","journal-title":"Int J Technol Assess Health Care"},{"issue":"7","key":"1182_CR33","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1634\/theoncologist.2014-0429","volume":"20","author":"NR Latimer","year":"2015","unstructured":"Latimer NR, Abrams KR, Amonkar MM, Stapelkamp C, Swann RS. Adjusting for the confounding effects of treatment switching-the BREAK-3 trial: dabrafenib versus dacarbazine. Oncologist. 2015;20(7):798\u2013805. https:\/\/doi.org\/10.1634\/theoncologist.2014-0429.","journal-title":"Oncologist"},{"issue":"5","key":"1182_CR34","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/cam4.643","volume":"5","author":"NR Latimer","year":"2016","unstructured":"Latimer NR, Bell H, Abrams KR, Amonkar MM, Casey M. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy. Cancer Med. 2016;5(5):806\u201315. https:\/\/doi.org\/10.1002\/cam4.643.","journal-title":"Cancer Med"},{"issue":"4","key":"1182_CR35","first-page":"16","volume":"2","author":"J Maervoet","year":"2016","unstructured":"Maervoet J, van Engen A, Latimer NR, Boehler Y-B, Holmstrom S. How can payer requirements be satisfied when treatment switching occurs? Value Outcomes Spotlight. 2016;2(4):16\u20138.","journal-title":"Value Outcomes Spotlight."},{"issue":"6","key":"1182_CR36","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.21037\/jtd-21-1924","volume":"14","author":"P Tankere","year":"2022","unstructured":"Tankere P, Boidot R, Bonniaud P, Zouak A, Foucher P, Milliere A, et al. Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort. J Thorac Dis. 2022;14(6):2034\u201344. https:\/\/doi.org\/10.21037\/jtd-21-1924.","journal-title":"J Thorac Dis"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01182-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:10:30Z","timestamp":1764605430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01182-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1182"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01182-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rachel E. Sanborn received honoraria from Illumina; served in a consulting or advisory role for AbbVie, Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, Curio Science, Daiichi Sankyo, GE HealthCare, Gilead, GSK, IDEOlogy Health, Inhibrx, Eli Lilly, Johnson & Johnson, MJH Life Sciences, OncLive, Pfizer, Sanofi-Aventis, and Ose Immunotherapeutics; received research funding from Merck and AstraZeneca (investigator-sponsored trials); and received travel support to a scientific meeting from HotSpot Therapeutics. Caicun Zhou received honoraria from Eli Lilly China, Sanofi, Boehringer Ingelheim, Roche, Merck Sharp & Dohme, Qilu Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals, Innovent Biologics, Alice Pharmaceuticals, C-Stone Pharmaceuticals, LUYE Pharma, TopAlliance Biosciences Inc., Amoy Diagnostics, and AnHeart Therapeutics; and served in a consulting or advisory role for Innovent Biologics, Qilu Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals, and TopAlliance Biosciences Inc. Ke-Jing Tang has no conflicts of interest that are directly relevant to the content of this article. Byoung Chul Cho received research funding from AstraZeneca, Champions Oncology, CJ Bioscience, Johnson & Johnson, Merck Sharp & Dohme, Dong-A ST, Yuhan Corporation, ImmuneOncia, Therapex, J INTS BIO, Vertical Bio AG, GI Innovation, and Cyrus Therapeutics; received royalties or licenses from Champions Oncology, Crown Bioscience, Imagen, and PearlRiver Bio GmbH; served in a consulting or advisory role for BeiGene, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Bristol Myers Squibb, CJ Bioscience, Cyrus Therapeutics, Ono Pharmaceutical, Yuhan Corporation, Pfizer, Eli Lilly, Guardant Health, Takeda, Merck Sharp & Dohme, Janssen, Gilead, Amgen, Daiichi Sankyo, Regeneron, Sanofi, AnHeart Therapeutics, Seagen, Harpoon Therapeutics, GSK, ArriVent Biopharma, BridgeBio, Kanaph Therapeutics, Cyrus Therapeutics, J INTS BIO, and Therapex; served in a leadership role for J INTS BIO; has stock ownership or other ownership interests with Theravance, Gencurix, BridgeBio, Kanaph Therapeutics, Cyrus Therapeutics, Interpark Bio, Convergence Corp, and J INTS BIO; reports employment with Yonsei University Health System; and other relationships with DAAN Biotherapeutics. Susanne Cheng served in an advisory role for Merck and AstraZeneca. Sanjay Popat served on advisory boards for Boehringer Ingelheim, Novartis, Amgen, Johnson & Johnson, Daiichi Sankyo, AstraZeneca, Bayer, Bristol Myers Squibb, Blueprint Medicines, Merck Serono, Guardant Health, BeiGene, Takeda, Eli Lilly, Roche, Turning Point Therapeutics, GSK, Merck Sharp & Dohme, Pfizer, Sanofi, and EQRx; served as an invited speaker for Medscape and VJOncology; has other relationships with Elsevier, Amgen, Merck Sharpe & Dohme, and Blueprint Medicines; served as a coordinating PI for ARIAD Pharmaceuticals, Boehringer Ingelheim, Celgene, Takeda, Turning Point Therapeutics, Roche, Johnson & Johnson, Bristol Myers Squibb, and Eli Lilly; served as a local PI for AstraZeneca, Roche, GSK, and Trizell; received research grants from Guardant Health; served in a leadership role for the British Thoracic Oncology Group and European Thoracic Oncology Platform; served in an advisory role for ALK Positive UK, International Association for the Study of Lung Cancer, Lung Cancer Europe, and the Ruth Strauss Foundation; served as an officer for the European Society of Medical Oncology; and served as a member of the board of directors for the Mesothelioma Applied Research Foundation. Akira Ono received payment or honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., Janssen Pharmaceutical K.K., Indica Labs, and Ono Pharmaceutical and research grants to their institution from AstraZeneca K.K., Chugai Pharmaceutical Co., and Janssen Pharmaceutical K.K. Shun Lu received consulting fees from AstraZeneca, Pfizer, Boehringer Ingelheim, HUTCHMED, Simcere Pharmaceutical, Zai Lab, GenomiCare, Yuhan Corporation, Roche, Menarini, and InventisBio Co. Ltd. and received honoraria from AstraZeneca, Roche, Hansoh Pharma, Jiangsu Hengrui Pharmaceuticals, HUTCHMED, Bristol Myers Squibb, BeiGene, and Eli Lilly. Margarita Majem received research funding from Roche, Bristol Myers Squibb, and AstraZeneca; received honoraria from Roche, AstraZeneca, MSD Oncology, Amgen, Bristol Myers Squibb, Pierre Fabre, Casen Recordati, Immedica, Johnson & Johnson, Novartis, Sanofi, Takeda, Pfizer, BeiGene, and Boehringer Ingelheim; received support for travel from Pfizer, Merck Sharp & Dohme, Roche, AstraZeneca, and Johnson & Johnson. Andres Aguilar received honoraria from Johnson & Johnson, Spain, Takeda, and Roche-Farma S.A.; and received support for travel from Merck Sharp & Dohme, Johnson & Johnson, Roche-Farma S.A., and Bristol Myers Squibb. Maria Del Rosario Garcia Campelo served in a consulting or advisory role for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, MSD Oncology, Novartis, Pfizer, Roche\/Genentech, and Takeda; served on a speakers bureau for Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, MSD Oncology, Novartis, Pfizer, Roche, Sanofi\/Aventis, and Takeda; and received travel, accommodations, or expenses from MSD Oncology, Pfizer, and Roche\/Genentech. Hidetoshi Hayashi received honoraria from Ono Pharmaceutical, Daiichi Sankyo, AstraZeneca K.K., Chugai Pharmaceutical Co., Eli Lilly Japan, Merck Sharp & Dohme K.K., Pfizer Japan, Nippon Boehringer Ingelheim, Merck, 3H Medi Solution, Novartis K.K., Bristol Myers Squibb, Amgen, Sysmex, and Takeda; received a manuscript fee from Guardant Health Japan; received research funding from IQVIA Services Japan K.K., Syneos Health K.K., EPS Corporation, Nippon Kayaku, Takeda, Merck Sharp & Dohme K.K., Amgen, Taiho Pharma, Bristol Myers Squibb, Janssen K.K., CMIC, Pfizer R&D Japan, Labcorp Development Japan K.K., Kobayashi Pharmaceutical, Pfizer Japan, Eisai, EP-CRSU CO, Shionogi, Otsuka, GSK K.K., Sanofi K.K., Chugai Pharmaceutical Co., Nippon Boehringer Ingelheim, SRL Medisearch Inc., PRA Health Sciences, Astellas, Ascent Development Services, Eisai, and Bayer; and has other relationships with Medical Review Co, Japanese Board of Cancer Therapy, and Japanese Society of Medical Oncology. Kang-yun Lee has no conflicts of interest that are directly relevant to the content of his article. Se-Hoon Lee served in a consulting or advisory role for Abion, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, IMBdx, ImmuneOncia, Johnson & Johnson, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Takeda; received honoraria from Amgen, AstraZeneca\/MedImmune, Bristol Myers Squibb, Merck Sharp & Dohme, Roche, and Yuhan Corporation; and received research funding from AstraZeneca, Daiichi Sankyo, Lunit, and Merck Sharp & Dohme. Angelo Delmonte served in an advisory role for Takeda, Novartis, AstraZeneca, Merck Sharp & Dohme, and Pfizer. Jorge Alatorre-Alexander received honoraria from AstraZeneca, Bristol Myers Squibb (Mexico), and Roche\/Genentech; served in a consulting or advisory role for AstraZeneca, Bristol Myers Squibb, MSD Oncology, Novartis, and Roche\/Genentech; served on a speakers bureau for AstraZeneca, Merck Sharp & Dohme, and Roche\/Genentech; and received travel, accommodations, or expenses from AstraZeneca and Roche. Gary Richardson received research funding from Bristol Myers Squibb, Roche\/Genentech, AstraZeneca, Merck, Takeda, BeiGene, Pfizer, CBT Pharmaceuticals, Corvus Pharmaceuticals, Novotech, Shanghai Fosun Pharmaceutical Development Co, Henlius, Five Prime Therapeutics, Alphamab Co., Boehringer Ingelheim, Adagene, Bio-Thera Solutions, ChemoCentryx, Curon BioPharma, D3 Bio, InventisBio Co. Ltd., Senz Oncology, GenFleet Therapeutics, GeneQuantum, Henlius, Keythera Pharma, LaNova Australia Pty Limited, Medicenna Therapeutics, Minghui Pharmaceutical, Neoleukin Therapeutics, PharmAbcine, RemeGen, Seagen, Surface Oncology, Eucure Biopharma, Janssen Oncology, ImmunGen, Imugene, Therapim, Zentalis, and Agenus. Victor Santos received honoraria from AstraZeneca, Bristol Myers Squibb Brazil, Daiichi Sankyo, GSK, Ipsen, Janssen, and Merck Sharp & Dohme; served in a consulting or advisory role for Johnson & Johnson; and received travel, accommodations, or expenses from Janssen. Christophe Dooms served on an advisory board for Janssen. Joshua K. Sabari served on an advisory board for AstraZeneca, Genentech, Johnson & Johnson, Pfizer, Regeneron, Sanofi, Takeda, and Mirati Therapeutics. Catherine A. Shu served on an advisory board for AstraZeneca, Genentech, Gilead, and Johnson & Johnson. Nicolas Girard received consulting fees from AbbVie, Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Roche, Johnson & Johnson, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Sivan Innovation, Mirati Therapeutics, Pfizer, Sanofi, and Takeda; received honoraria from AbbVie, Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Roche, Johnson & Johnson, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Sivan Innovation, Mirati Therapeutics, Pfizer, Sanofi, and Takeda; received support for meetings\/travel from Janssen, Amgen, and Bristol Myers Squibb; and served in an advisory role for Roche. Aaron S. Mansfield received grants or contracts from Novartis and Verily; received consulting fees from Rising Tide and Triptych Health; received honoraria from Johnson & Johnson, BeiGene, Chugai Pharmaceutical Co., IDEOlogy Health, Antoni van Leeuwenhoek Kanker Instituut, AXIS Medical Education, Johnson & Johnson, Intellisphere, Answers in CME, Miami International Mesothelioma Symposium, and Immunocore; received support for meetings\/travel from Roche; served in an advisory role for AbbVie, AstraZeneca, Bristol Myers Squibb, Genentech\/Roche, and Takeda; served in a leadership role for Mesothelioma Applied Research Foundation and Friends of Patan Hospital; and has other relationships with Bristol Myers Squibb. \nKeunchil Park served in an advisory role for AstraZeneca, Eli Lilly, Ono Pharmaceutical, Bristol Myers Squibb, Merck Sharp & Dohme, Blueprint Medicines, Amgen, Merck, Loxo Oncology, AbbVie, Daiichi Sankyo, Boehringer Ingelheim, Johnson & Johnson, Eisai, and Puma Biotechnology; served on a speakers bureau for Boehringer Ingelheim; and received research funding from AstraZeneca and Merck Sharp & Dohme. Yichuan Xia is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Archan Bhattacharya is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Nasuh Buyukkaramikli is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Nolen Perualila is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Joris Diels is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Sandip Acharya is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Conor Chandler is an employee of Evidera and Evidera received payment from Johnson & Johnson for the conduct of this study. Irina Proskorovsky is an employee of Evidera and Evidera received payment from Johnson & Johnson for the conduct of this study. Lindsay Dearden is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Honeylet Wortman-Vayn is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Parthiv J. Mahadevia is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Roland E. Knoblauch is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Trishala Agrawal is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Mahadi Baig is an employee of Johnson & Johnson and may hold stock in Johnson & Johnson. Enriqueta Felip served in a consulting or advisory role for AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Roche, Gilead, GSK, Johnson & Johnson, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Pfizer, Regeneron, Sanofi, Takeda, Turning Point Therapeutics, and Daiichi Sankyo; served on a speakers bureau for Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Roche, Genentech, Johnson & Johnson, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme, PeerVoice, Pfizer, Sanofi, Takeda, and TouchONCOLOGY; received travel, accommodations, or expenses from AstraZeneca, Johnson & Johnson, and Roche; and has other relationships with Grifols, Hospital Universitari Parc Tauli, Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica, and ETOP IBCSG Partners Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The trial was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines (as defined by the International Council for Harmonisation), applicable regulatory requirements, and the policy on bioethics and human biologic samples of the trial sponsor, Janssen Research and Development.\u00a0The study protocols, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent prior to treatment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at\n                      \n                      . As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Study concept and design: RES, YX, AB, NB, NP, JD, SA, CC, LD, HWV, PJM, REK, EF. Data acquisition: RES, CZ, KJT, BCC, SC, SP, AO, SL, MM, AA, MDRGC, HH, KYL, SHL, AD, JAA, GR, VS, CD, JKS, CAS, NG, ASM, KP, TA, MB, EF. Data analysis: YX, AB, NB, NP, JD, SA, CC, IP, LD, HWV, PJM, REK. Data interpretation: all authors. Drafting or critically revising manuscript: all authors. Approval of final version: all authors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}